162 results
Page 5 of 9
8-K
EX-99.1
shvwo0az326z 7b83
30 Oct 19
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
7:43am
8-K
EX-99.1
06hjbn t43u
30 Jul 19
Regulation FD Disclosure
7:46am
8-K
EX-99.1
aotr83ttv
25 Jul 19
Alkermes Plc Reports Second Quarter 2019 Financial Results
7:05am
8-K
EX-99.2
ls8fnjts nsai3kt4z
25 Jul 19
Alkermes Plc Reports Second Quarter 2019 Financial Results
7:05am
8-K
EX-99.1
wi0yz8bb4jh9
15 Jul 19
Regulation FD Disclosure
7:33am
8-K
EX-99.2
xrf 944yj947
25 Apr 19
Alkermes Plc Reports First Quarter 2019 Financial Results
7:05am
8-K
EX-99.1
hm3s61s5
25 Apr 19
Alkermes Plc Reports First Quarter 2019 Financial Results
7:05am
8-K
EX-99.2
7n383885 a0
14 Feb 19
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
0snsvjw8
1 Feb 19
Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application
4:33pm
8-K
EX-99.1
40i0u 56x
7 Jan 19
Results of Operations and Financial Condition
7:13am
8-K
EX-99.1
9mfx d1ynx1pdyy3lnf
29 Nov 18
Alkermes Announces Positive Topline Results FromENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
7:17am
8-K
8pt5s0
2 Nov 18
Regulation FD Disclosure
12:00am
8-K
EX-99.1
nt0c5a15ulwn
2 Nov 18
Regulation FD Disclosure
12:00am
8-K
vzjdqleu
30 Oct 18
Regulation FD Disclosure
7:55am